ThromboGenics’ Jetrea receives NICE approval for eye condition treatment
Known as ocriplasmin, Jetrea is administered through a one-time, single intravitreal injection to break down the protein fibers which cause the abnormal traction between vitreous and macula leading
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.